A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | MicrobiomeTrials← Back to trialsNCT06557265
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2024-06-13Est. Completion: 2027-04
Enrollment target: 120 participants Locations- Nkarta Investigational Site, Little Rock, Arkansas, United States
- Nkarta Investigational Site, Tustin, California, United States
- Nkarta Investigational Site, Gainesville, Florida, United States
- Nkarta Investigational Site, Miami, Florida, United States
- Nkarta Investigational Site, Plantation, Florida, United States
- Nkarta Investigational Site, Tampa, Florida, United States
- Nkarta Investigational Site, Atlanta, Georgia, United States
- Nkarta Investigational Site, Chicago, Illinois, United States
- Nkarta Investigational Site, New Orleans, Louisiana, United States
- Nkarta Investigational Site, Worcester, Massachusetts, United States
- Nkarta Investigational Site, Ann Arbor, Michigan, United States
- Nkarta Investigational Site, Summit, New Jersey, United States
- Nkarta Investigational Site, New York, New York, United States
- Nkarta Investigational Site, Stony Brook, New York, United States
- Nkarta Investigational Site, Syracuse, New York, United States
- Nkarta Investigational Site, Dallas, Texas, United States
Other microbiome trials you might be interested in
Kidney DiseaseNephrotic Syndrome
Kidney diseases related to the immune system include, nephrotic syndrome, glomerulonephritis, membranous nephropathy, lu…
Bethesda, United States
Lupus Nephritis (LN)
This study is researching a particular group of experimental drugs administered for a short period in the treatment of p…
Rochester, United StatesEst. completion Sep 9, 2029
Nkarta Investigational Site, Houston, Texas, United StatesNkarta Investigational Site, Parkville, Victoria, AustraliaNkarta Investigational Site, Manati, Puerto RicoRecruiting
Lupus Erythematosus, Systemic
The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants w…
Multiple LocationsEst. completion Mar 29, 2030